Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

2seventy bio, Inc. - Common Stock (NQ:TSVT)

5.000 UNCHANGED
Last Price Updated: 4:00 PM EDT, May 12, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about 2seventy bio, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
News headline image
Bristol Myers-2seventy Bio Halt Phase 3 Trial For Abecma In Newly Diagnosed Myeloma Patients, Speeds Path To Profitability ↗
2seventy bio halts enrollment in its KarMMa-9 trial for Abecma, saving $80 million and focusing on profitability by 2025. Despite the decision, the company expects strong growth following FDA approval... 
Via Benzinga
News headline image
2seventy bio Provides Update on KarMMa-9 Study and Previews Anticipated Strong Third Quarter Revenue Performance
From 2seventy bio, Inc.
Via Business Wire
News headline image
2seventy bio to Participate in the 2024 Morgan Stanley Global Healthcare Conference
From 2seventy bio
Via Business Wire
News headline image
A Preview Of 2seventy bio's Earnings ↗
 
Via Benzinga
News headline image
2seventy bio Reports Second Quarter Financial Results and Recent Operational Progress
From 2seventy bio, Inc.
Via Business Wire
News headline image
2seventy bio to Report Second Quarter 2024 Financial Results on August 7, 2024
From 2seventy bio, Inc.
Via Business Wire
News headline image
3 Hidden Stock Gems That Wall Street Is Overlooking ↗
If you play the long game and have a suitable risk tolerance, you can find overlooked stock gems like these three. 
Via InvestorPlace
News headline image
Novo Nordisk Buys 2seventy's Hemophilia A Program, Divestiture Supports Exclusive Focus On Abecma ↗
2seventy Bio finalized an asset purchase agreement with Novo Nordisk involving the Hemophilia A program and in vivo gene editing technology. The 2seventy bio team will join Novo Nordisk, focusing on... 
Via Benzinga
News headline image
2seventy bio Announces Sale of Hemophilia A Candidate and MegaTAL In Vivo Gene Editing Technology to Novo Nordisk for up to $40 million
From 2seventy bio, Inc.
Via Business Wire
News headline image
2seventy bio to Participate in Upcoming Investor Conferences
From 2seventy bio, Inc.
Via Business Wire
News headline image
TSVT Stock Earnings: 2seventy bio Meets EPS, Misses Revenue for Q1 2024 ↗
TSVT stock results show that 2seventy bio met analyst estimates for earnings per share but missed on revenue for the first quarter of 2024. 
Via InvestorPlace
News headline image
2seventy bio Reports First Quarter Financial Results and Recent Operational Progress
From 2seventy bio, Inc.
Via Business Wire
News headline image
2seventy bio to Report First Quarter 2024 Financial Results on May 8, 2024
From 2seventy bio, Inc.
Via Business Wire
News headline image
FDA Mandates "Boxed Warning" For Bristol Myers, Johnson & Johnson CAR-T-Based Blood Cancer Therapies ↗
Following an investigation announced in November last year, the FDA said on Thursday that it would now require boxed warnings—the highest safety-rel 
Via Benzinga
News headline image
FDA Approves Bristol-Myers/2seventy Bio's Abecma For Earlier Use In Pretreated Blood Cancer Patients With Updated Boxed Warning On Secondary Cancer ↗
FDA approves Bristol-Myers Squibb and 2seventy Bio Abecma (ide-cel) for relapsed or refractory multiple myeloma after ≥2 prior therapies. Extends progression-free survival by 13.3 months vs. standard... 
Via Benzinga
News headline image
2seventy bio Announces Completion of Oncology and Autoimmune Pipeline Divestiture to Regeneron
From 2seventy bio, Inc.
Via Business Wire
News headline image
U.S. FDA Approves Bristol Myers Squibb and 2seventy bio’s Abecma for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma After Two Prior Lines of Therapy
From Bristol Myers Squibb
Via Business Wire
News headline image
2seventy bio Announces Appointments of Eli Casdin and Charles Newton to Board of Directors
From 2seventy bio, Inc.
Via Business Wire
News headline image
Why Science Applications International Shares Are Trading Lower By Over 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗
Shares of Science Applications International Corporation (NYSE: SAIC) fell sharply during Monday’s session after the company reported financial fourth-quarter EPS below estimates. 
Via Benzinga
News headline image
FDA Adcomm Favors Expanded Use Of Johnson & Johnson, Bristol Myers' CAR-T Therapies For Type Of Blood Cancer ↗
FDA's adcomm recommends expanded use of Bristol Myers Squibb's Abecma for triple-class exposed relapsed or refractory multiple myeloma, based on Phase 3 study results. Positive vote for Johnson &... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why Nuvei Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket ↗
Shares of Nuvei Corp (NASDAQ: NVEI) rose sharply in today’s pre-market trading following a report indicating the company is in buyout talks with Advent International. Nuvei shares jumped 14.1% to... 
Via Benzinga
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday ↗
Pre-market stock movers are the perfect way to start the week as we dive into the biggest stories moving shares on Monday! 
Via InvestorPlace
News headline image
FDA Advisory Committee Votes in Favor of Bristol Myers Squibb’s and 2seventy bio’s Abecma for Triple-Class Exposed Multiple Myeloma in Earlier Lines of Therapy
From Bristol Myers Squibb
Via Business Wire
News headline image
Why Cardlytics Shares Are Trading Higher By Around 37%; Here Are 20 Stocks Moving Premarket ↗
Shares of Cardlytics, Inc. (NASDAQ: CDLX) rose sharply in today’s pre-market trading after the company reported better-than-expected fourth-quarter earnings. 
Via Benzinga
News headline image
Arcellx's Lead Asset Can Potentially Outperform Bristol-Myers Squibb, Johnson & Johnson's Multiple Myeloma Cell Therapies: Morgan Stanley ↗
Morgan Stanley initiates coverage on Arcellx. Uncover the potential of ddBCMA in blood cancer treatment, featuring a differentiated CAR-T platform. Analysts project $5 billion in peak sales. 
Via Benzinga
News headline image
TSVT Stock Earnings: 2seventy bio Misses EPS, Misses Revenue for Q4 2023 ↗
TSVT stock results show that 2seventy bio missed analyst estimates for earnings per share and missed on revenue for the fourth quarter of 2023. 
Via InvestorPlace
News headline image
2seventy bio Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Operational Progress
From 2seventy bio, Inc.
Via Business Wire
News headline image
2seventy bio to Report Fourth Quarter and Full Year 2023 Financial Results and Participate in Upcoming Investor Conferences
From 2seventy bio, Inc.
Via Business Wire
News headline image
Earnings Scheduled For March 5, 2024 ↗
Companies Reporting Before The Bell • NIO (NYSE:NIO) is estimated to report quarterly loss at $0.51 per share on revenue of $2.29 billion. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.